top of page
  • Writer's pictureFriday Capital


Updated: Jun 29, 2022

Although these days the race to develop a COVID-19 vaccine is taking centre stage in the current biosciences environment, oncology still plays a key role as being the next largest area for investment activity. Before COVID-19 struck, oncology represented nearly half of the buy-side transactions for the large pharma dealmakers, and topped US venture capital funding by disease area. Most oncology therapy deals are characterised by M&A (70%) whereas licensing makes up much less of the total (27%).

Our Q4 2020 report provides an in-depth analysis of this dynamic investment environment along with the latest developments in the field of immuno-oncology therapeutics.

Table of contents:

  • Deal Landscape

  • M&A Deals

  • Licensing Deals

  • Venture Capital

  • Key Immuno-Oncology Therapies

  • CAR-T


  • Neoantigen Vaccines

  • Checkpoint Inhibitors

  • Combination Therapies

  • Biomarkers

  • Companion Diagnostics

  • Next Generation Sequencing

  • Clinical Trials

You can download our report from here:

Download • 3.39MB

For further details and enquiries please contact Anthony Vago at


bottom of page